Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook

Simply Wall St.03-03

Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616158353?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355","is_english":true,"pubTime":"2026-03-03 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616158353","market":"hk","top_or_hot":-1,"title":"Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook","media":"Simply Wall St.","content":"<div>\n<p>Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-valuation-check-after-fda-nod-for-sa\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-valuation-check-after-fda-nod-for-sa><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-valuation-check-after-fda-nod-for-sa\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-valuation-check-after-fda-nod-for-sa","article_id":"2616158353","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-valuation-check-after-fda-nod-for-sa","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616158353","pubTimestamp":1772519261,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum and innovation.\nSee our latest analysis for Edwards Lifesciences.\nThe FDA approval of SAPIEN M3 and Edwards Lifesciences' 2026 sales outlook arrive as the share price trades at US$87.18, with a 7-day share price return of 5.75% and a 1-year total shareholder return of 22.12%. This suggests momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","EW":"爱德华兹","BK4588":"碎股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","BK4082":"医疗保健设备","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4504":"桥水持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H"},"translate_title":"FDA批准SAPIEN M3和2026年增长前景后Edwards Lifesciences(EW)的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1.5},"content_text":"Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum and innovation. See our latest analysis for Edwards Lifesciences. The FDA approval of SAPIEN M3 and Edwards Lifesciences' 2026 sales outlook arrive as the share price trades at US$87.18, with a 7-day share price return of 5.75% and a 1-year total shareholder return of 22.12%. This suggests momentum has been building around new product progress and evolving views on risk. If this heart valve news has you thinking more broadly about medical technology, it could be a good moment to scan 28 healthcare AI stocks for fresh ideas in the healthcare space. With the shares at US$87.18, modestly below the average analyst target and with double digit recent returns, the key question is whether Edwards Lifesciences still offers upside or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 9.6% Undervalued Edwards Lifesciences' most followed narrative points to a fair value of $96.46 per share versus the recent $87.18 close, framing a modest valuation gap tied to execution on growth projects and margins.  The recent approval of the Sapien M3 in Europe as the world's first transcatheter mitral valve replacement system signals Edwards' ability to address large, unmet patient needs, which could result in substantial revenue growth. Edwards' ongoing investments in surgical innovation, such as the RESILIA tissue technology, are likely to expand access and adoption of its cardiovascular therapies globally, potentially improving net margins and bolstering revenue.  Read the complete narrative. Curious what has to happen for that fair value to hold up? The narrative leans on solid top line expansion, steadier margins and a rich future earnings multiple. The exact mix of growth and profitability expectations might surprise you. According to the most widely followed view, Edwards Lifesciences' future hinges on mid single digit to high single digit annual revenue growth, rising earnings and a premium valuation multiple that remains above the broader U.S. Medical Equipment group. Analysts building this narrative use a discount rate of 7.69% and assume the company can maintain healthy profit margins while funding product development and market expansion, including transcatheter therapies and surgical structural heart solutions. They also model a future P/E in the low 30s on projected earnings and tie that to a revenue base that is expected to be higher than today, alongside earnings that are meaningfully above current levels. That combination of growth plus a premium multiple is what supports the $96.46 fair value estimate, even though the gap versus the current price is not especially wide. Result: Fair Value of $96.46 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change if tariffs hit margins harder than expected, or if competitive pressure slows TAVR procedure growth in key markets like Japan. Find out about the key risks to this Edwards Lifesciences narrative. Another Angle: High P/E Tells a Different Story While the narrative and our cash flow work point to shares trading around fair value with a 3.3% discount to the SWS DCF model, the simple earnings multiple paints a tighter picture. Edwards trades on a P/E of 47.8x, well above the Medical Equipment industry at 30.9x, a peer average of 29.8x and a fair ratio of 36.2x that the market could move toward over time. That kind of premium can work if the growth and margin story holds, but it also leaves less room for disappointment. The question for you is whether Edwards has earned that gap, or if you would rather wait for the valuation to cool a little. See what the numbers say about this price — find out in our valuation breakdown. NYSE:EW P/E Ratio as at Mar 2026Next Steps With mixed signals on valuation and growth expectations, the next move is really yours. Act while the data is fresh and weigh up 2 key rewards and 3 important warning signs. Looking for more investment ideas? If you stop with just one company, you might miss other opportunities that fit your style. Put a few minutes into lining up your next watchlist candidates now.  Target value first and check out 45 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet. Prioritise strength and scan our solid balance sheet and fundamentals stocks screener (41 results) to find businesses with the financial resilience you might want behind your capital. Spot potential early movers by reviewing the screener containing 24 high quality undiscovered gems that many investors may not be watching closely yet.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edwards Lifesciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616158353","isCrawlerRequest":true}